Aptar Pharma has announced a deal with French biotech Aceso Therapeutics related to development of Aceso’s ACT-101 antisense oligonucleotide for the treatment of cystic fibrosis. According to Aptar, its subsidiary Nanopharm will provide development services for an inhaled formulation of ACT-101 as well as services related to delivery. The company notes that the new work fits into its ongoing project regarding inhaled and nasal delivery of biologics.
Earlier this year, Aptar said that Nanopharm would conduct a feasibility study for Covirix Medical, evaluating delivery of an inhaled antiviral via the Orbital DPI. The company recently announced that Nanopharm’s facility in Cwmbran, Wales had received GMP certification.
Nanopharm General Manager Gemma Budd commented, “Cystic fibrosis remains a devastating disease with significant unmet need. Partnering with Aceso Therapeutics enables us to apply our formulation and inhalation science expertise to an innovative oligonucleotide asset. We are proud to contribute our expertise to this early-stage development program.”
Aceso Therapeutics CEO Thomas Tran said, “By partnering with Nanopharm, Aceso Therapeutics aims to accelerate the development of ACT-101 towards clinical evaluation, exploring its potential through direct delivery to the lung. Nanopharm’s proven track record in inhaled and nasal drug product development, combined with the wider scientific depth within Aptar Pharma, gives us confidence as we continue to advance our ASO platform. This collaboration marks an important milestone for Aceso and for the continued development of potential new approaches for cystic fibrosis.”
Read the Aptar Pharma press release
